GENB (Generate Biomedicines) Current Deferred Revenue: $21.19 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENB Generate Biomedicines Inc GENB
6 GF Score
Price $15.63
! 1 Warning Sign
View Full Analysis

What is Generate Biomedicines Current Deferred Revenue?

Generate Biomedicines GENB +4.48% 6 Current Deferred Revenue is $21.19 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Generate Biomedicines's current deferred revenue for the quarter that ended in Dec. 2025 was $21.19 Mil.

Generate Biomedicines Current Deferred Revenue Related Terms

Generate Biomedicines Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Current Deferred Revenue Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Current Deferred Revenue
42.43 21.19

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Current Deferred Revenue 42.43 21.19
GENB
6GF Score
Generate Biomedicines Inc GENB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $21.19 Mil mean?
Generate Biomedicines (GENB) has a Current Deferred Revenue of $21.19 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Current Deferred Revenue too high?
Generate Biomedicines' current Current Deferred Revenue is $21.19 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Current Deferred Revenue compare to ZYME and DMRA?
Generate Biomedicines' Current Deferred Revenue of $21.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Current Deferred Revenue is $21.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Current Deferred Revenue of $21.19 Mil. The current Current Deferred Revenue is $21.19 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Current Deferred Revenue is $21.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.63
Price